Is Compounded Tirzepatide Still Legal?
Tirzepatide moved before semaglutide, on a clause most summaries drop. The dates, the litigation still running, and why one date is later than usually quoted.
Tirzepatide reached the end of the compounding road before semaglutide did, and it got there by a slightly different mechanism. Anyone who learned the story from the semaglutide side has the shape roughly right and the dates wrong.
This is not a question about whether compounded tirzepatide works, or whether it is equivalent to the branded product. It is a question about which legal mechanism permitted it and whether that mechanism is still there.
The clause that moves the date
Most summaries of this say enforcement discretion for state-licensed pharmacies ended on 18 February 2025. That is what the FDA’s first condition says. It is not what actually governed.
The agency wrote two conditions joined by a disjunction. It said it did not intend to take action against compounders operating under section 503A until 18 February 2025, or until the date of the district court’s decision on the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, whichever is longer.
The court decided that motion on 5 March 2025. The second date fell later than the first, so the second one applied.
This is a small thing that changes a two-and-a-half week window, and it is the kind of detail that gets lost the third time a fact is repeated. If a source gives you 18 February with no mention of the litigation clause, it has quoted half a sentence.
The dates, in order
| Date | What happened |
|---|---|
| 2 October 2024 | FDA declares the tirzepatide shortage resolved |
| 19 December 2024 | FDA re-evaluates and reaffirms that determination |
| 18 February 2025 | First 503A condition expires (60 days from the announcement) |
| 5 March 2025 | Court decides the preliminary injunction motion — 503A discretion ends |
| 19 March 2025 | 503B outsourcing facilities: discretion ends |
| 7 May 2025 | District court upholds the FDA’s shortage determination |
| March 2026 | Fifth Circuit hears argument on appeal |
Two legal categories in that table are routinely merged, and they should not be. 503A is a state-licensed pharmacy or physician compounding for an individual patient against a prescription. 503B is an outsourcing facility producing at larger scale without patient-specific prescriptions. Different conditions, different deadlines, two weeks apart.
What the shortage listing was actually doing
United States law lets a compounder work with a bulk active ingredient in circumstances an ordinary pharmacy could not. One of those circumstances is the drug being on the FDA drug shortage list.
Tirzepatide went onto that list during the demand surge. That listing — not any judgement that compounded versions were equivalent to the branded product — is what opened the route.
The permission was always conditional, and attached to a temporary fact. When the fact stopped being true, the permission went with it.
What remains
The 503A pathway did not disappear when the shortage resolved. Patient-specific compounding by a state-licensed pharmacy rests on a different part of the statute, one that does not depend on shortage status.
What constrains it is the rule against compounding a product that is essentially a copy of a commercially available drug. The FDA treats a compounded product as essentially a copy when it has the same active ingredient as a marketed drug, in the same, similar or easily substitutable strength, usable by the same route of administration.
Tirzepatide injection is commercially available. A compounded tirzepatide injection is therefore, on its face, a copy.
The exception is documented clinical need: a prescriber determining and recording that a compounded product contains a change producing a significant difference for an identified individual patient. A verified sensitivity to an excipient in the approved product is the kind of thing that can meet it.
Price is not. Convenience is not. Preference is not. Those are the reasons most often given in practice, and none of them is the test the statute sets.
This is not legal advice, and it is not a view on whether a compounded product is equivalent to a branded one. Where a specific prescription sits is a question for the prescriber and the pharmacy under the law of the place they operate in. The dates and conditions above come from the FDA’s own statements, linked in the sources.
The part that is still open
The district court upheld the FDA’s shortage determination on 7 May 2025. The case went up to the Fifth Circuit, which heard argument in March 2026, and no final ruling has issued.
That leaves an unusual situation: the enforcement position has been stable for well over a year and compounders have been operating under it, while the determination underneath it is still being contested on appeal.
The practical reading is that the current framework is what applies now, not that it is settled forever. Anything you read about this that predates a Fifth Circuit ruling is describing an interim state.
Outside the United States
None of the above transfers. The compounding framework described here is US law, and the EU has no equivalent of the 503A bulks mechanism. Tirzepatide is authorised centrally through the European Medicines Agency.
The consequence in Europe is narrower rather than wider. A product that is not the authorised one does not become lawful because an American shortage list once said something. That question runs through EU medicines law instead, and the answer there is less accommodating than the compounding debate makes it sound.
The practical part
If the source of a vial changes, the arithmetic usually changes with it.
A branded pen delivers a fixed amount per dose and hides the concentration entirely. A compounded vial does not: it has a concentration, and what appears on the syringe depends on it. Moving between those two is where errors cluster — the reconstitution arithmetic is the same as for any vial, and the calculator will convert a quantity and a volume into syringe units.
What is worth writing down at that moment is the concentration and the date, not the click count. A pen’s numbers do not describe a vial, and a record that mixes the two quietly stops meaning anything. If the vial came from a compounder, the discard window is worth writing down too — it is rarely the same as the one printed on a branded pen.
Frequently asked questions
Is compounded tirzepatide still legal in 2026?
The route that most compounded tirzepatide travelled on is closed. It depended on tirzepatide being listed on the FDA drug shortage list, and that listing ended. Enforcement discretion ran out for state-licensed pharmacies compounding under section 503A on 5 March 2025, and for outsourcing facilities under section 503B on 19 March 2025. What remains is a narrow patient-specific route under 503A, constrained by the prohibition on compounding a product that is essentially a copy of a commercially available drug. Cost, convenience or preference do not satisfy that test. A documented clinical need for a specific patient can.
Why is 5 March given rather than 18 February?
Because the FDA wrote two conditions, not one, and most summaries quote only the first. The agency said it did not intend to act against 503A compounders until 18 February 2025, "or until the date of the district court's decision on the plaintiffs' preliminary injunction motion in Outsourcing Facilities Association v. FDA, whichever is longer." The court decided that motion on 5 March 2025. Because the second date fell later than the first, the second one governed. Sources that print 18 February have dropped the clause that changed the answer.
Is the litigation over?
No. The district court upheld the FDA's shortage determination on 7 May 2025, and the case went to the United States Court of Appeals for the Fifth Circuit, which heard argument in March 2026. No final ruling has issued. This matters for how the current position should be read: the enforcement posture has been stable since spring 2025 and compounders have been operating under it, but the underlying determination is still being litigated. A decision could change the framework, and anyone reading a dated summary should check whether it predates a ruling.
Is tirzepatide in the same position as semaglutide?
Broadly the same framework, on a different timetable, and tirzepatide moved first. The FDA declared the tirzepatide shortage resolved on 2 October 2024 and re-evaluated that determination on 19 December 2024. Semaglutide followed on 21 February 2025. The deadlines then fell in sequence: tirzepatide 503A on 5 March 2025 and 503B on 19 March 2025, semaglutide 503A on 22 April 2025 and 503B on 22 May 2025. Neither compound currently appears on the FDA drug shortage list or on the 503B bulks list.